SPECIAL REPORT
MOST SHARED
- Wednesday's Economic News Crunch Could Tilt Markets
- The 'Real' Jobless Rate: 17.5% Of Workers Are Unemployed
- The Social Media Gaming Threat
- NBA D-League On The Rise
- Obama Reiterates Commitment to Boost US-India Ties
- Stifling Anger at Work Can Kill, Survey Finds
- Australia Wheat Exporters Face Challenges: GrainCorp
- Japan Export Rebound Eases Fear of New Recession
- Citi Mortgage Reveals What Treasury Won't
- S&P to Hit 1,200 by Year-End: Chief Investor
- Amended Berkshire Hathaway Filing Indicates No Secret Stock Stakes at End of Q3
- Facebook's Biggest-Ever Holiday Shopping Season
- Facebook's New Dual Class Structure - Slow Steps to an IPO
- 5 Big Bank Stocks Investors Should Consider: Strategists
- Gambling Drunk, Texting to Live And America's On Sale - Your Emails
- Nov. 24: Unusual Volume Leaders
- NBA D-League On The Rise
- AIG Board OKs CEO Pay; Benmosche Agrees to Stay
- Obama Reiterates Commitment to Boost US-India Ties
- FDIC's Bair Cautions on Risks in Bank Break-Up Plan
- Wednesday's Economic News Crunch Could Tilt Markets
- Call Me Crazy: Confessions of a Black Friday Shopper
- 'Very Blah' Christmas Is Coming for UK Retailers
- US Firms Hit by Payroll Taxes at Exactly the Wrong Time
- Citi Mortgage Reveals Something the US Treasury Won't
- In Time for Holidays: More Gloom and Doom on Economy
PHARMA'S MARKET VIDEO
RSS FEED
Pharma's Market
![]() |
CNBC.com |
CEO Fred Hassan was in Miami when doctors dropped the bomb on Vytorin and Zetia at the American College of Cardiology meeting.
And then he and his people shifted into crisis mode which resulted in the mid-week announcement of massive job cuts. I've occasionally mentioned this on the blog before, but because the drug industry is such a huge part of the NJ economy, the Star-Ledger has a handful of reporters covering pharma. But the paper kind of operates in the shadow of The New York Times and The Wall Street Journal. Nonetheless, it often cranks out stuff like this that you might not read anywhere else.
In her daily cholesterol-drug prescriptions note to clients, Catherine Arnold at Credit Suisse says on April 4th that Vytorin and Zetia combined had a 14.7 percent share of the total prescriptions in the segment. That's down from 16.3 percent pre-ACC. She's going to keep a close eye on the scripts for the next two months and says she expects "increased volatility" during that time.
Deutsche Bank's Barbara Ryan in a research note to clients this morning says there could be an immediate 15 percent drop in Vytorin/Zetia prescriptions from March levels. But she's not certain how much staying power it'll have. She writes: "The recommendation for use (of Vytorin and Zetia) 'as a last resort' seemingly comes with a stamp of consensus medical expert approval, which based upon our observations and conversations is NOT the case." The caps are hers.
![]() |
CNBC.com |
In the early going this morning, SGP is once again one of the top percentage gainers in the sector. Leading the way, though, is Wyeth [WYE
Loading...
()
] which was featured in a very bullish article in Barron's over the weekend and is the biggest dollar gainer.
Elan [ELN
Loading...
()
] is also benefiting from the Barron's write-up because the companies are partners on a promising Alzheimer's drug. Also from Barron's: Pfizer [PFE
Loading...
()
] now ranks 19th on the list of New York Stock Exchange companies with the largest short positions. According to the publication, the number of PFE shares being shorted went up 4.1 million, or 7.2 percent, from March 14th to March 31st.
Questions? Comments?










